Arbutus director receives 78,800-share option grant

Arbutus Biopharma Corp director Roger Sawhney received a fully vested stock option grant covering 78,800 common shares.

Accepted by SEC EDGAR 06/10/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Arbutus Biopharma Corp director Roger Sawhney received a fully vested stock option grant covering 78,800 common shares. The option was granted at an exercise price of $4.24 per share, matching the closing price of the company’s common shares on Nasdaq on the grant date.

The option is immediately exercisable and expires on June 8, 2036. This transaction reflects an equity-based compensation award and does not involve any open-market purchase or sale of Arbutus Biopharma shares.

Insider Trade Summary

Grant/Award: 78,800 shares

Grant/Award 1 txn

Insider Sawhney Roger

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	78,800	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 78,800 contracts (Direct)

Footnotes (2)

1. F1. Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
2. F2. The option is fully vested and exercisable as of the date of the grant.

Key Figures

Option grant size: 78,800 shares Exercise price: $4.24 per share Total options after grant: 78,800 options +2 more

5 metrics

Option grant size 78,800 shares Stock Option (Right to Buy) granted to director

Exercise price $4.24 per share Conversion or exercise price for the option

Total options after grant 78,800 options Total derivative securities held following transaction

Grant date June 8, 2026 Option grant and exercise date

Expiration date June 8, 2036 Option term end for the stock option grant

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, Common Shares, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 4.2400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

derivative transaction financial

"derivativeTransactionCount: 1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Arbutus Biopharma (ABUS) report for Roger Sawhney?

Arbutus Biopharma reported that director Roger Sawhney received a stock option grant for 78,800 common shares. The option was awarded as equity compensation, is fully vested on the grant date, and provides future rights to buy shares at a fixed exercise price.

How many Arbutus Biopharma (ABUS) shares are covered by the new option grant?

The new stock option grant to director Roger Sawhney covers 78,800 underlying common shares. These options give him the right to purchase that number of Arbutus Biopharma shares at a preset exercise price any time before the stated expiration date.

What is the exercise price of Roger Sawhney’s Arbutus Biopharma (ABUS) stock options?

The exercise price for Roger Sawhney’s stock option grant is $4.24 per common share. According to the disclosure, this amount reflects the closing price of Arbutus Biopharma’s common shares on the Nasdaq Stock Market on the date the option was granted.

When do Roger Sawhney’s Arbutus Biopharma (ABUS) options vest and expire?

Roger Sawhney’s stock option is fully vested and exercisable as of the grant date, meaning there is no waiting period. The option has a long-term horizon, with an expiration date of June 8, 2036, providing substantial time to decide whether to exercise.

Did Roger Sawhney buy or sell Arbutus Biopharma (ABUS) shares in the market?

The filing shows a grant of stock options to Roger Sawhney, not an open-market trade. It records an equity award transaction rather than a purchase or sale of existing Arbutus Biopharma shares on the stock market, reflecting compensation rather than trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sawhney Roger

(Last) (First) (Middle)

C/O ARBUTUS BIOPHARMA CORPORATION

701 VETERANS CIRCLE

(Street)

WARMINSTER PENNSYLVANIA 18974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arbutus Biopharma Corp [ ABUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.24(1)	06/08/2026		A		78,800		06/08/2026(2)	06/08/2036	Common Shares	78,800	$0	78,800	D

Explanation of Responses:

1. Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.

2. The option is fully vested and exercisable as of the date of the grant.

Remarks:

	/s/ Tuan Nguyen as attorney-in-fact for Roger Sawhney	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)